类风湿关节炎患者接受JAK抑制剂治疗时HBV再激活风险不可忽视:填补证据空白
该回顾性分析纳入台湾大学医院2015至2023年接受TNF抑制剂、利妥昔单抗或JAK抑制剂治疗的类风湿关节炎患者,比较HBV再激活风险。在HBsAg阴性/anti-HBc阳性患者中,JAK抑制剂总体再激活率为2.9%(10.3/1000人年),高于TNF抑制剂的0.9%(2.8/1000人年);HBsAg阳性患者中50%的JAK抑制剂使用者出现肝炎 flare。作者认为JAK抑制剂治疗下HBV再激活风险不可忽视,尤其JAK1选择性较高者,需更大规模注册或前瞻性研究验证。
要点
- HBsAg阴性/anti-HBc阳性RA患者中,JAK抑制剂再激活率2.9%(10.3/1000人年),高于TNF抑制剂的0.9%(2.8/1000人年)。
- 各JAK抑制剂中乌帕替尼再激活率最高(6.5%,42.8/1000人年),其次巴瑞替尼(4.7%,19.2/1000人年),托法替布最低(1.0%,2.7/1000人年)。
- HBsAg阳性RA患者中,50%的JAK抑制剂使用者出现肝炎 flare,强调 vigilant monitoring 和预防的重要性。
核心结论
- RA患者接受JAK抑制剂治疗时HBV再激活风险不可忽视,尤其JAK1选择性较高的JAK抑制剂。
- 需要更大规模注册或前瞻性研究验证这些发现。
研究设计与样本
- 回顾性分析台湾大学医院2015至2023年接受TNF抑制剂、利妥昔单抗或JAK抑制剂(托法替布、巴瑞替尼、乌帕替尼)治疗的RA患者。
- 纳入有基线HBV状态(HBsAg、anti-HBc、anti-HBs、HBV DNA)的患者,共35例HBsAg阳性患者和339例HBsAg阴性/anti-HBc阳性(已消退HBV感染)患者。
- 主要结局为HBsAg阳性患者的肝炎 flare 和HBsAg阴性/anti-HBc阳性患者的HBsAg血清学逆转。
主要发现
- 已消退HBV感染患者中,TNF抑制剂再激活风险低(0.9%,2.8/1000人年),利妥昔单抗较高(3.2%,15.1/1000人年),JAK抑制剂总体为2.9%(10.3/1000人年)。
- 各JAK抑制剂中,乌帕替尼发生率最高(6.5%,42.8/1000人年),其次巴瑞替尼(4.7%,19.2/1000人年),托法替布最低(1.0%,2.7/1000人年)。
- HBsAg阳性患者中,50%的JAK抑制剂使用者出现肝炎 flare。
局限性
- 原文结论指出需要更大规模注册或前瞻性研究验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: HBV reactivation is a critical concern for patients with autoimmune disease undergoing immunosuppressive therapy. Despite data on HBV reactivation risks associated with biologics, the impact of the new targeted immunosuppressive agents-Janus kinase inhibitors (JAKis)-remains unclear. This study aimed to evaluate the risk of HBV reactivation among patients with RA treated with JAKis, compared with those receiving TNF inhibitors (TNFis) or rituximab. METHOD: We conducted a retrospective analysis of patients with RA treated at the National Taiwan University Hospital from 2015 to 2023. Patients with available baseline HBV status [HBsAg, hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs), HBV DNA] who received TNFis, rituximab, or JAKis (tofacitinib, baricitinib, upadacitinib) were included. The primary outcomes were hepatitis flare in HBsAg-positive patients and HBsAg seroreversion in HBsAg-negative/anti-HBc-positive patients. RESULTS: We included 35 HBsAg-positive patients and 339 patients with resolved HBV infection (HBsAg-negative/anti-HBc-positive). Among those with resolved HBV infection, the reactivation risk was low with TNFis (0.9%, 2.8/1000 person-years), and higher with rituximab (3.2%, 15.1/1000 person-years) and JAKis overall (2.9%, 10.3/1000 person-years). Among individual JAKis, upadacitinib had the highest incidence (6.5%, 42.8/1000 person-years), followed by baricitinib (4.7%, 19.2/1000 person-years), and tofacitinib (1.0%, 2.7/1000 person-years). Among HBsAg-positive patients, 50% of JAKi users developed a hepatitis flare, emphasizing the importance of vigilant monitoring and prophylaxis. CONCLUSION: Our findings reveal a non-negligible risk of HBV reactivation among RA patients receiving JAKi therapy, particularly with the more JAK1-selective JAKis. Larger registry or prospective studies are needed to validate these findings.
引用
- Lan TY, Lee TJ, Chang TW, et al. Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap. Rheumatology (Oxford). 2025. PMID: 40794751. doi:10.1093/rheumatology/keaf419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。